Earnings Feed
Start Free
Revolution Medicines, Inc.·4

Jun 17, 7:51 PM ET

Horn Margaret A 4

4 · Revolution Medicines, Inc. · Filed Jun 17, 2026

Research Summary

AI-generated summary of this filing

Updated

Revolution Medicines (RVMD) COO Margaret Horn Sells Shares, Exercises Options

What Happened

  • Margaret A. Horn, Chief Operating Officer of Revolution Medicines (RVMD), reported option exercises and open-market sales. On June 15 and June 17, 2026 she exercised multiple option tranches (acquiring a total of 108,?—see details below) at strikes of $40.74, $29.80 and $26.50, and sold 60,400 shares on 6/15 and 29,600 shares on 6/17 in open-market trades. The two recent sales generated proceeds of approximately $9.67M (6/15) and $4.74M (6/17), ~ $14.41M total. The filing also shows a prior sale on 2025-06-16 of 3,575 shares for ~$558K. Some derivative entries are reported at $0.00 reflecting conversion/settlement of the derivative instruments upon exercise.

Key Details

  • Transaction dates & prices:
    • 2026-06-15: Exercised 15,546 shares @ $40.74 (cost $633,344) and 44,854 shares @ $29.80 (cost $1,336,649); sold 60,400 shares @ weighted avg $160.17 (proceeds $9,674,304). Multiple sale prices ranged $160.00–$160.3550 per share (weighted avg reported).
    • 2026-06-17: Exercised 573 @ $40.74 (cost $23,344), 3,302 @ $29.80 (cost $98,400), 25,725 @ $26.50 (cost $681,713); sold 29,600 @ weighted avg $160.12 (proceeds $4,739,679). Multiple sale prices ranged $160.00–$160.48 (weighted avg reported).
    • 2025-06-16: Sold 3,575 @ weighted avg $156.12 (proceeds $558,126). Multiple trade prices ranged $156.1105–$156.8250.
  • Sales total (6/15 + 6/17): ~90,000 shares for ~ $14.41M.
  • The filing includes corresponding derivative disposition lines reported at $0.00 (reflecting conversion of options/derivatives upon exercise).
  • Footnotes of note:
    • F1: Some trades were made pursuant to a 10b5‑1 trading plan adopted March 12, 2026.
    • F4: Some sales were executed under a Rule 10b5‑1 instruction to satisfy tax withholding on RSU vesting.
    • F2/F6: Filing references RSUs (73,050 and 66,201) as part of holdings.
    • F8/F9/F10: Option grants subject to monthly vesting schedules (1/48th per month) from various vesting commencement dates (March 1, 2023/2024/2025).
  • Shares owned after the transactions: not specified in the excerpt of the filing provided.
  • Filing timeliness: Reported on June 17, 2026 for transactions dated June 15–17, 2026 (no late‑filing flag indicated in provided data).

Context

  • These entries show exercised options (transaction code M) followed by open‑market sales (S). When option exercises are immediately followed by market sales, it often reflects a cashless exercise or sales to cover exercise costs and tax withholding; here the filing explicitly notes a 10b5‑1 tax withholding instruction for RSU vesting. No inference should be made about insider sentiment beyond the record of purchases/exercises and sales — the filing is factual reporting of exercises and routine / planned sales.

Insider Transaction Report

Form 4
Period: 2026-06-15
Revolution Medicines, Inc.RVMD
Horn Margaret A
Chief Operating Officer
Transactions
  • Exercise/Conversion

    Common Stock

    [F1][F2]
    2026-06-15$40.74/sh+15,546$633,344→ 173,768 total
  • Exercise/Conversion

    Common Stock

    [F1][F2]
    2026-06-15$29.80/sh+44,854$1,336,649→ 218,622 total
  • Sale

    Common Stock

    [F1][F3][F2]
    2026-06-15$160.17/sh−60,400$9,674,304→ 158,222 total
  • Sale

    Common Stock

    [F4][F5][F6]
    2025-06-16$156.12/sh−3,575$558,126→ 154,647 total
  • Exercise/Conversion

    Common Stock

    [F1][F6]
    2026-06-17$40.74/sh+573$23,344→ 155,220 total
  • Exercise/Conversion

    Common Stock

    [F1][F6]
    2026-06-17$29.80/sh+3,302$98,400→ 158,522 total
  • Exercise/Conversion

    Common Stock

    [F1][F6]
    2026-06-17$26.50/sh+25,725$681,713→ 184,247 total
  • Sale

    Common Stock

    [F1][F7][F6]
    2026-06-17$160.12/sh−29,600$4,739,679→ 154,647 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1][F8]
    2026-06-15−15,546→ 75,648 total
    Exercise: $40.74Exp: 2035-02-28→ Common Stock (15,546 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1][F9]
    2026-06-15−44,854→ 75,052 total
    Exercise: $29.80Exp: 2034-02-28→ Common Stock (44,854 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1][F8]
    2026-06-17−573→ 75,075 total
    Exercise: $40.74Exp: 2035-02-28→ Common Stock (573 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1][F9]
    2026-06-17−3,302→ 71,750 total
    Exercise: $29.80Exp: 2034-02-28→ Common Stock (3,302 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1][F10]
    2026-06-17−25,725→ 114,275 total
    Exercise: $26.50Exp: 2033-02-28→ Common Stock (25,725 underlying)
Footnotes (10)
  • [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026.
  • [F10]One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
  • [F2]Includes 73,050 restricted stock units ("RSUs").
  • [F3]This transaction was executed in multiple trades in prices ranging from $160.00 to $160.3550, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F4]Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of RSUs after July 15, 2023.
  • [F5]This transaction was executed in multiple trades in prices ranging from $156.1105 to $156.8250, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F6]Includes 66,201 RSUs.
  • [F7]This transaction was executed in multiple trades in prices ranging from $160.00 to $160.48, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F8]One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
  • [F9]One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Signature
/s/ Jack Anders, as Attorney-in-fact for Margaret Horn|2026-06-17

Documents

1 file
  • 4
    form4.xmlPrimary